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STANDFIRST: Brooke Nickel and colleagues consider the evidence that removing the cancer label in 
very low risk conditions that are unlikely to cause harm if left untreated, may be one helpful strategy 
to address issues of overdiagnosis and overtreatment  
 
There is a growing body of research showing that disease labels can impact people’s psychological 
responses and their decisions about management options. The use of more medicalised labels can 
increase both concern about illness and desire for more invasive treatment.1 For low risk cancers 
where there is evidence of overdiagnosis2 and calls to replace the term cancer,3-6 we consider the 
potential implication of removing the cancer label. 
 
Our changing understanding of the prognosis of cancers 
Some ‘cancers’ are non-growing or so slow-growing that they will never cause harm to patients if left 
undetected.2 A prime example of this type of cancer is low risk papillary thyroid cancer. Autopsy 
studies reveal there is a large reservoir of undetected papillary thyroid cancer that never causes 
harm7 and there is now substantial evidence of a dramatic increase in the incidence of thyroid 
cancer in many developed countries. This increase has been predominantly driven by an increase in 
small papillary thyroid cancers, with mortality remaining largely unchanged.8 Detection of these 
small papillary thyroid cancer has mainly been a result of the advent of new technologies, increased 
access to health services and thyroid cancer screening.5 Studies demonstrate that rates of 
metastases, progression to clinical disease and tumour growth in patients diagnosed with small 
papillary thyroid cancer who receive immediate surgery are comparable to those who follow active 
surveillance.9 10 
 
Likewise, for both low risk ductal carcinoma in situ (DCIS) and localised prostate cancer, detection 
strategies have become controversial as long-term outcomes for both conditions have been shown 
to be excellent11 12 and there is evidence and concern about overdiagnosis and overtreament.2 Given 
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the potential harms of overtreatment of DCIS, active surveillance is now being trialled internationally 
as an alternative management approach.13-15 Active surveillance is also recognised as a safe and 
desirable management option for localised prostate cancer in current clinical practice, although 
invasive procedures such as a prostatectomy are still common and conventional treatment options 
for men diagnosed with localised disease.  
 
Beyond low risk thyroid cancer, DCIS and prostate cancer, there is some evidence and informed 
speculation that melanoma in situ, small lung cancers and certain small kidney cancers may be 
considered low risk cancers and subject to similar overdiagnosis and overtreatment.2 16-18 
 
The cancer label 
For decades ‘cancer’ has been associated with death. This association has been ingrained in society 
with public health messaging that ‘cancer screening saves lives’. This promotion has been used with 
the best of intentions, but in part deployed to induce feelings of fear and vulnerability in the 
population and then offer hope through screening19 (Box 1). 
  
While conservative management approaches, such as active surveillance, are becoming an option 
for some patients with cancer, there is still a strong perception that aggressive treatments are 
always required.20 Recent studies on men diagnosed with localised prostate cancer have found that 
emotional distress of the diagnosis may motivate men to choose more aggressive treatment.21 
However, not treating prostate cancer and following active surveillance also increases men’s levels 
of anxiety, rates of depression and fear of cancer recurrence.22 Importantly, almost a quarter of men 
who initially choose to manage their prostate cancer with active surveillance opt for surgery or 
radiation therapy within 5 years for non-biological reasons.23  
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Box 1. Impact of the cancer label 
Widespread enthusiasm for cancer screening 
• Landmark US survey found that 87% of adults believe routine cancer screening is almost 
always a good idea and 74% of adults said that finding cancer early (most or all of the 
time) saves lives.24 
• A British survey of 2024 men and women aged 50-80 years found that almost 90% of 
people believe that screening is ‘almost always a good idea’ and 49% said that they would 
be tested for cancer even it if was untreatable.25 
• In studies on breast and cervical cancer it has been shown that women are often highly 
resistant to the idea of less intensive screening, with concerns about the frequency of 
screening intervals and that the changes are being made due to cost cutting 
considerations rather than on the basis of improved evidence about managing the cancer 
in question.26-28 
• Interviews with more than 10,000 members of the European public demonstrates that 
92% of women and 89% of men overestimate (or do not know) the mortality benefit of 
breast and prostate cancer screening.29 
 
Strong desire for surgery 
• In a study including healthy US adults it was found that when treatment was framed as 
being harmful, participants were significantly more inclined to opt for surgery compared 
to medication (65% v. 38%, x2=11.40, p=0.001), even though doing so may increase their 
chance of death.20 
• A study of 394 women found that when ductal carcinoma in situ (DCIS) was described as a 
non-invasive cancer 47% of women preferred surgery over non-surgical treatment options 
such as medication or active surveillance, whereas only 34% preferred surgery when it 
was described as ‘breast lesion’ and 31% when it was described as ‘abnormal cells’ 
(p≤0.001).30 
 
Uncertainty around active surveillance of cancer 
• In a 5-year nationwide follow-up study it was found that 23% of men discontinued active 
surveillance for their low to intermediate risk prostate cancer diagnosis for non-biological 
reasons (20% patient preference and 3% other reasons).23 
 
Psychological repercussions 
• Across a sample of 1521 men diagnosed with localised prostate cancer it was found that 
men who were more emotionally distressed at the time of diagnosis were more likely to 
choose surgery over active surveillance (RRR 1.07; 95% CI 1.01, 1.14; p=0.02).21 
• A population-based prospective cohort study of 341 men demonstrated that at 9-11 years 
after diagnosis men who started active surveillance and/or watchful waiting for their low 
risk localised prostate cancer had higher levels of distress and hyperarousal than men 
who had radiation or high-dose-rate brachytherapy (AMD=5.9; 95% CI [0.5, 11.3] and 
AMD=5.4; 95% CI [0.2, 10.5], respectively) and higher levels of distress and avoidance 
than men who had low-dose-rate brachytherapy (AMD=5.3; 95% CI [0.2, 10.3] and 
AMD=7.0; 95% CI [0.5, 13.5], respectively).22 
 
One potential strategy to calibrate expectation and to avoid unnecessary testing and treatment for 
these low risk cancers may be to remove the cancer label from conditions unlikely to cause harm if 
left untreated. This strategy has been proposed by several international experts,3-6 including a 
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National Institutes of Health state of the science conference panel and a National Cancer Institute 
working group. In line with this, the chief medical officer of the American Cancer Society Otis W. 
Brawley has stated: “We need a 21st-century definition of cancer instead of a 19th-century 
definition of cancer, which is what we’ve been using.”31 Notwithstanding the challenges, we agree 
there is now a clear need to re-label a number of precancerous conditions and low risk cancers 
(Table 1). 
 
Evidence about labelling supports move to change 
There is now evidence from several studies that describing a condition using more medicalised 
labels, including the use of the term ‘cancer’, can lead to an increased preference for more invasive 
management options (Table 2),1 and this supports calls to remove the cancer label, where 
appropriate. The increased desire for more invasive management may be particularly important to 
consider in cancers which have a high public profile such as DCIS and prostate cancer. In DCIS it has 
been shown that women are increasingly opting for more aggressive treatments such as 
mastectomy and bilateral mastectomy rather than lumpectomy,32 33 even though these treatments 
do not improve breast cancer-specific survival.34 Similarly, in localised prostate cancer where active 
surveillance has been a recommended management option for a number of years, studies have 
shown that the majority of men still prefer to opt for radical prostatectomy or radiation therapy 
(external-beam radiation or brachytherapy) to manage their diagnosis.23 35  
 
How clinicians categorise conditions and recommend treatments may also be influenced by labels.36 
37 For clinicians a number of factors may drive them to overdiagnose and overtreat, albeit 
unconsciously and unintentionally. According to a recent review of the literature,38 potential drivers 
of overdiagnosis in the professional domain include fear of litigation or missing disease, an 
overemphasis on the need to diagnose, a lack of awareness of potential iatrogenic harms, and the 
challenge of doing nothing rather than something. Removing the cancer label from low risk 
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conditions may help shift clinician perspectives and enable them to feel comfortable recommending 
less invasive treatment options to patients.  
 
Examples where the cancer label has been removed 
Removing the cancer label from conditions has occurred previously when there is clear evidence 
that tumours are largely indolent and very unlikely to cause harm (Table 3). An early example of this 
was when the World Health Organisation and International Society of Urological Pathologists jointly 
decided to remove the cancer label from bladder tumours. It was agreed by a multidisciplinary group 
of experts that a condition known to rarely progress to invasive cancer should not be called ‘cancer’. 
In this change papilloma and grade 1 carcinoma of the bladder were reclassified as papillary 
urothelial neoplasia of low malignant potential.39 Similarly, a change in the description of cervical 
abnormalities found during a Pap smear from cervical intraepithelial neoplasia (ie. cancer), to 
squamous intraepithelial lesions, using the Bethesda System, has helped support more women to 
follow active surveillance. This change reflected important advances in the biological understanding 
of cervical neoplasia as well as advances in cervical screening technology and was driven by a 
motivation to help provide more uniform, evidence-based, clearer and less anxiety-provoking 
terminology.40  
 
A more recent example of removing the cancer term occurred with ‘non-invasive encapsulated 
follicular variant of papillary thyroid carcinoma’ (EFVPT). This condition was shown to behave 
indolently and rarely exhibit metastases, and was thus reclassified to ‘non-invasive follicular thyroid 
neoplasm with papillary-like nuclear features’ (NIFTP).41 Under the auspices of the Endocrine 
Pathology Society working group a panel of international experts largely made up of pathologists 
reviewed the current criteria of hundreds of cases of patients who had been followed for at least 10 
years. Findings demonstrated that none of the patients whose tumours stayed within their capsules 
had any evidence of cancer and this resulted in agreement to change the label, a decision endorsed 
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numerous leading professional societies internationally. To provide simplified and reproducible 
criteria to assist in the pathological diagnosis of NIFTP the six main consensus nuclear features were 
grouped together and scored.41 The aims of removing the cancer label in this condition were to 
highlight the indolent nature of the tumour, decrease unnecessary additional therapies42 43, reduce 
the potential psychological and financial burden associated with being diagnosed with cancer, and 
change how clinicians counsel their patients.  
 
Significant as these changes almost certainly have been, we were unable to find any formal 
evaluation of their impact on practice, clinician behaviour or patient outcomes.  
 
Removing the cancer label 
To help make progress on removing the cancer label from potential low risk conditions, we suggest a 
number of concrete actions within clinical practice, medical education, and research (Box 2). To start 
the major reform process of removing the cancer label, we propose an initial global Round Table 
which could potentially include involvement from key cancer classification and staging groups such 
as the World Health Organisation (WHO) Classification of Tumours Group, the International 
Collaboration on Cancer Reporting (ICCR), and the American Joint Committee on Cancer (AJCC), as 
well as government health agencies and leading professional cancer societies including the National 
Cancer Institute (NCI) in the United States, the American Cancer Society (ACS), and similar 
organisations from other nations. We also strongly endorse the inclusion and engagement of both 
citizens/consumers in initial Round Table discussions and in any subsequent policy decision-making 
process. Since the identification and treatment of cancer impact the lives of both the public and 
patients their input and preferences are vital when reaching decisions. In line with contemporary 
community expectations of independence, formulation of any recommendations for reform would 
be undertaken in a process free of conflicts of interest.  
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Box 2. Actions to help make progress on removing the cancer label 
Clinical practice 
• Clinicians should initiate discussions about the likely benign nature of low risk conditions, 
the possibility of overdiagnosis and overtreatment, and the option of less invasive 
managements such as active surveillance, both before and after diagnostic interventions 
• Clinicians should convey risk information using event rates (or absolute risks) in order to 
show the long-term outcomes for people with low risk conditions, for both active 
surveillance and immediate treatment, over relevant timeframes such as 10 or 20 years44 
 
Medical education 
• Implementation of new medical education curricula can help students and working 
clinicians gain a deeper understanding of overdiagnosis and strategies to communicate 
about low risk conditions 
• Information should be designed and widely promulgated for the public about 
overdiagnosis and the benign nature of some low risk conditions. 
 
Research 
• Calculation of precise estimates on the proportions of patients affected by changing 
terminology 
•  More studies of long-term outcomes of less invasive management options for low risk 
conditions  
• Testing possible alternative labels  
 
Removing the cancer label from some of the low risk candidates (e.g. low risk thyroid cancer and 
localised prostate cancer) will pose a more challenging task as they display evidence of invasion 
under the microscope whereas others have no invasive elements (e.g. DCIS). Bringing together a 
broadly representative multidisciplinary group, such as the one we propose, could start the process 
of re-labelling by addressing these challenges, as well as current uncertainties and disagreement. 
Discussions could start by reviewing current evidence on the risk of progression of each of the 
identified low risk conditions, establishing standardised agreement in pathology reporting and 
diagnostic criteria across each condition, and then identify – where appropriate – an alternative 
label that would address the biological and clinical characteristics of the lesion. This process may 
also have a supplementary effect of enabling pathologists to address and resolve currently 
concerning levels of disagreement around important thresholds.45 46 
 
As history demonstrates change and innovation in medicine are often resisted.47-49 Changing 
something as fundamental as our shared understanding of the nature and meaning of cancer, 
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including a change in nomenclature, will therefore face many challenges and barriers, underscoring 
the need for a multi-stakeholder process. For example, recent qualitative evidence suggests 
clinicians treating low risk papillary microcarcinomas do not currently see the merits of removing the 
cancer label.37 Similarly focus groups with a random sample of community members found 
resistance to removing the cancer label from some participants, although a strong openness among 
many others.50  
 
Following a collective approach that involves informed citizens and consumers will provide input and 
insights – both positive and negative – about how a new label might help recalibrate expectations 
for detection, follow-up and treatment. For current patients already diagnosed, the impact of a 
change in a label might have unexpected results. Downgrading a conditions’ label may cause 
patients to revise the nature and extend of follow-up, and question the need for additional 
treatments which could potentially reduce overtreatment, and any associated harmful psychological 
effects.1 On the other hand, current patients might perceive that a new label undermines their 
current care, including changing what support they have access to.51 Thus, any re-labelling process 
needs to consider not only the prospective impact of the new label, but also the impact on 
individuals already diagnosed with the condition, and provide education, support and guidance 
where necessary in how to proceed. 
 
While it is clear there is a need to re-label some low risk conditions currently labelled as ‘cancer’, it is 
vital to be cognisant of the potential to also cause harm. A label may provide beneficial effects 
including an explanation and symptom validation for those presenting with symptoms, as indicated 
in other non-cancer conditions.52 53 There may also be implications for receiving benefits within the 
healthcare system, making some individuals ineligible for certain forms of support from government 
or health insurers. Furthermore, once labelled with cancer, individuals become part of a wider 
community of cancer survivors. Removing the cancer label could mean many patients may perceive 
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that they have been falsely classified, are no longer cancer survivors and may have potentially 
received unnecessary treatments. This may cause psychological distress and confusion for some 
patients. As a patient advocate recently suggested, doctors discussing why a change in diagnostic 
terminology has occurred may help individuals accept such a change.51  
 
Moving forward 
‘Indolent lesions of low malignant potential’ (IDLE) and variations of other similar labels including 
‘abnormal cells’, ‘neoplasia’ and ‘micro-tumour’ have been proposed to help convey the favourable 
prognosis of these lesions,3 5  while others have suggested complete “elimination of the use of the 
anxiety-producing term carcinoma” for example in the case of DCIS.4 Although the label needs to be 
biologically accurate it also needs to be something patients can understand and that will not induce 
disproportionate concern. Civil society and consumer involvement in the re-labelling process will be 
imperative to help ensure that a potential reclassification of these conditions will be understood and 
supported by the broader community.  
 
Careful consideration, deliberation and endorsement from cancer classification and staging groups, 
health agencies and cancer societies, as well as major civil society and consumer organisations is 
needed to begin and move this process forward. We believe that as a starting point, Round Table 
discussions involving key stakeholder representatives free from conflicts of interests should be 
considered to establish agreement and ensure that any future change is consistently and uniformly 
applied. In the meantime, there is much to be done now across clinical, education and research 
settings.  
 
Ultimately removing the cancer label will create controversy and take time. The end result however 
will help ensure appropriate evidenced-based care moving forward for both future and current 
patients. Learning from past examples and planning a formal future evaluation of practice 
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implications and patient outcomes is vital to ensuring safe and effective reform. While it remains 
unclear exactly how to best move forward, it is clear we cannot continue to tell many people they 
have cancer, when that label may be doing them more harm than good.  
 
KEY MESSAGES:  
• A growing body of research demonstrates that the labels used to describe medical 
conditions can influence treatment decisions and psychological responses 
 
• Removing the cancer label from low risk conditions that are unlikely to cause harm if left 
untreated has been proposed by several international experts as one potential strategy to 
address overdiagnosis and overtreatment, however to date no change has been made 
 
• To start the major reform process, we endorse Round Table discussions involving key 
cancer classification and staging groups, health agencies, cancer societies and citizens and 
consumer groups, with participants free from any conflicts of interest  
 
• Learning from past examples and planning a formal evaluation of practice implications 
and patient outcomes is vital as a way of both evaluating the changes and ensuring safety 
moving forward  
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Table 1. Examples of candidate tumour types that could be considered for re-labelling  
 
Type of cancer Risk of tumour 
progression  
Disease-specific 
mortality  
Conventional treatment 
options  
Harms associated with invasive 
treatments 
Intrathyroidal 
papillary thyroid 
cancer (<1cm in 
size) 
3.8% over a period 
of 10 or more 
years 
<1% at 20 years Thyroidectomy; hemi-
thyroidectomy 
Surgical complications including 
problems with voice and calcium 
levels; need for life-long thyroid 
hormone replacement medication 
and its associated side-effects; out-
of-pocket costs; psychological 
harms 
Low and 
intermediate grade 
DCIS (stage 0 
breast cancer) 
~14-53% over a 
period of 10 or 
more years 
Breast cancer-
specific mortality 
rate is 3.3% at 20 
years 
Lumpectomy +/- 
radiotherapy; mastectomy 
+/- reconstruction   
Surgical complications including 
persistent pain; lymphedema; skin 
burns; long-term cardiovascular 
and pulmonary toxicity; out-of-
pocket costs; psychological harms 
Localised Prostate 
cancer (Gleason 
≤6) 
 
~18% over a period 
of 20-30 or more 
years 
1.2% at 10 years Radical prostatectomy; 
radiation therapy; active 
surveillance  
Surgical complications including 
impotence and incontinence; skin 
burns, long-term cardiovascular and 
pulmonary toxicity; out-of-pocket 
costs; psychological harms  
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Table 2.
 Summary of preferences for more invasive management by label*
 
 
Study More medical label† (%) Less medical label (%) Difference in 
preferences between 
labels (%) 
p-value 
Copp, 201754 Polycystic ovary syndrome 70 Hormonal imbalance 53 17 >0.05 
McCaffery, 
201555 
Pre-invasive breast  
cancer cells 
40 A normal cells 33 7 0.23 
Omer, 201330 Non-invasive cancer 47 Lesion, abnormal cells 32.5 14.5 <0.001 
Scherer, 
2013**56 
Gastro-oesophageal reflux 
disease (GERD) 
74 No label  67 7 >0.1 
Scherer, 
2015**57 
Pink-eye 60 Eye infection 58 8 >0.1 
Azam, 201058 Broken bone, fracture, 
greenstick fracture,  
hairline fracture 
39 Crack in the bone 20 20 <0.025 
*adapted from Nickel et al, 2017;1 data combined where applicable and mean percentages reported 
**significant two-way interaction between the more medical label and interest in ineffective medications 
found in the study 
 
 
 
 
 
Table 3. Examples of where the cancer label has been previously removed or changed 
 
Original nomenclature New nomenclature Year of 
change 
Group/s initiating change Reason for change 
Papilloma and grade 1 
carcinoma of the bladder 
Papillary urothelial neoplasia 
of low malignant potential 
1998 The World Health 
Organisation & 
International Society of 
Urological Pathology 
To provide better correlation 
of these lesions with their 
biologic behaviour using 
uniform technology39 
Cervical Intraepithelial 
Neoplasia (CIN)* 
Squamous Intraepithelial 
Lesion (SIL) 
2001 The Bethesda System 
Workshop Group 
(initiated by the Division 
of Cancer Prevention and 
Control, National Cancer 
Institute)  
To reflect important advances 
in biological understanding of 
cervical neoplasia and cervical 
screening technology40 
Non-invasive encapsulated 
follicular variant of papillary 
thyroid carcinoma (EFVPTC) 
Non-invasive follicular thyroid 
neoplasm with papillary-like 
nuclear features (NIFTP) 
2016 The Endocrine Pathology 
Society working group 
To highlight the low risk of 
adverse outcome of this 
tumour and reduce 
psychological and clinical 
consequences associated 
with the diagnosis41 
*original nomenclature still being used in the UK 
 
